These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 26001593)
1. Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease. Romero A; Acosta-Eyzaguirre D; Sanz J; Moreno F; Serrano G; Díaz-Rubio E; Caldés T; Garcia-Saenz JÁ Transl Res; 2015 Dec; 166(6):783-7. PubMed ID: 26001593 [TBL] [Abstract][Full Text] [Related]
3. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients. Oshiro C; Kagara N; Naoi Y; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S Breast Cancer Res Treat; 2015 Apr; 150(2):299-307. PubMed ID: 25736040 [TBL] [Abstract][Full Text] [Related]
4. Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer. Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H Cancer Sci; 2015 Nov; 106(11):1582-9. PubMed ID: 26353837 [TBL] [Abstract][Full Text] [Related]
5. Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer. Kodahl AR; Ehmsen S; Pallisgaard N; Jylling AMB; Jensen JD; Laenkholm AV; Knoop AS; Ditzel HJ Mol Oncol; 2018 Jun; 12(6):925-935. PubMed ID: 29689598 [TBL] [Abstract][Full Text] [Related]
6. A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers. Jelovac D; Beaver JA; Balukrishna S; Wong HY; Toro PV; Cimino-Mathews A; Argani P; Stearns V; Jacobs L; VanDenBerg D; Kessler J; Jeter S; Park BH; Wolff AC Hum Pathol; 2014 Apr; 45(4):880-3. PubMed ID: 24444464 [TBL] [Abstract][Full Text] [Related]
7. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Higgins MJ; Jelovac D; Barnathan E; Blair B; Slater S; Powers P; Zorzi J; Jeter SC; Oliver GR; Fetting J; Emens L; Riley C; Stearns V; Diehl F; Angenendt P; Huang P; Cope L; Argani P; Murphy KM; Bachman KE; Greshock J; Wolff AC; Park BH Clin Cancer Res; 2012 Jun; 18(12):3462-9. PubMed ID: 22421194 [TBL] [Abstract][Full Text] [Related]
8. PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA. Kim ST; Lira M; Deng S; Lee S; Park YS; Lim HY; Kang WK; Mao M; Heo JS; Kwon W; Jang KT; Lee J; Park JO Oncotarget; 2015 Nov; 6(37):40026-35. PubMed ID: 26498688 [TBL] [Abstract][Full Text] [Related]
9. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Board RE; Wardley AM; Dixon JM; Armstrong AC; Howell S; Renshaw L; Donald E; Greystoke A; Ranson M; Hughes A; Dive C Breast Cancer Res Treat; 2010 Apr; 120(2):461-7. PubMed ID: 20107891 [TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759 [TBL] [Abstract][Full Text] [Related]
11. Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging. García-Saenz JA; Ayllón P; Laig M; Acosta-Eyzaguirre D; García-Esquinas M; Montes M; Sanz J; Barquín M; Moreno F; Garcia-Barberan V; Díaz-Rubio E; Caldes T; Romero A BMC Cancer; 2017 Mar; 17(1):210. PubMed ID: 28330468 [TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers. Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032 [TBL] [Abstract][Full Text] [Related]
13. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues. Ney JT; Froehner S; Roesler A; Buettner R; Merkelbach-Bruse S Arch Pathol Lab Med; 2012 Sep; 136(9):983-92. PubMed ID: 22938585 [TBL] [Abstract][Full Text] [Related]
14. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373 [TBL] [Abstract][Full Text] [Related]
15. Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women. Chung TKH; Cheung TH; Yim SF; Yu MY; Chiu RWK; Lo KWK; Lee IPC; Wong RRY; Lau KKM; Wang VW; Worley MJ; Elias KM; Fiascone SJ; Smith DI; Berkowitz RS; Wong YF Gynecol Oncol; 2017 Aug; 146(2):334-339. PubMed ID: 28587748 [TBL] [Abstract][Full Text] [Related]
16. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women. Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324 [TBL] [Abstract][Full Text] [Related]